Rapidly progressive glomerulonephritis classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Rapidly progressive glomerulonephritis}} | {{Rapidly progressive glomerulonephritis}} | ||
{{CMG}} | {{CMG}} {{AE}} {{JSS}} | ||
==Overview== | ==Overview== | ||
Rapidly progressive glomerulonephritis is classified on the basis of cause of [[Glomerulus|glomerular]] injury.The [[Immunofluorescence|immunoflourescent microspcopic]] findings are used in determining the cause of glomerular injury. | |||
==Classification== | ==Classification== | ||
RPGN is classified on the basis of the cause of | RPGN is classified on the basis of the cause of glomerular injury and the findings from light and immunofluorescence microscopy.<ref name="pmid3287904">{{cite journal| author=Couser WG| title=Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. | journal=Am J Kidney Dis | year= 1988 | volume= 11 | issue= 6 | pages= 449-64 | pmid=3287904 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3287904 }} </ref><ref name="pmid9507491">{{cite journal| author=Couser WG| title=Pathogenesis of glomerular damage in glomerulonephritis. | journal=Nephrol Dial Transplant | year= 1998 | volume= 13 Suppl 1 | issue= | pages= 10-5 | pmid=9507491 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9507491 }} </ref>. | ||
===Type I=== | ===Type I=== | ||
* Type I RPGN is characterized by the presence of [[autoantibodies]] directed against the [[glomerular basement membrane]] (GBM). | * Type I RPGN is characterized by the presence of [[autoantibodies]] directed against the [[glomerular basement membrane]] (GBM)<ref name="pmid8909258">{{cite journal| author=Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ et al.| title=Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. | journal=Am J Pathol | year= 1996 | volume= 149 | issue= 5 | pages= 1695-706 | pmid=8909258 | doi= | pmc=1865281 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8909258 }} </ref>. | ||
* Type I also known as anti-[[GBM]] glomerulonephritis. | * Type I also known as anti-[[GBM]] [[Glomerular disease|glomerulonephritis.]] | ||
* The antibodies formed are known as anticollagen antibodies and react against type IV [[collagen]] of [[GBM]].<ref name="robbins">{{cite book |author=Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. |title=Robbins and Cotran pathologic basis of disease |publisher=Elsevier Saunders |location=St. Louis, MO |year=2005 |pages=pp976-8 |isbn=0-7216-0187-1 |oclc= |doi=}}</ref> | * The antibodies formed are known as anticollagen antibodies and react against type IV [[collagen]] of [[GBM]].<ref name="robbins">{{cite book |author=Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. |title=Robbins and Cotran pathologic basis of disease |publisher=Elsevier Saunders |location=St. Louis, MO |year=2005 |pages=pp976-8 |isbn=0-7216-0187-1 |oclc= |doi=}}</ref> | ||
* The antibodies can be produced by a stimulus such as viral [[Upper respiratory tract infection|URTI]] that exposes alveolar collagen membrane or it can be idiopathic. | * The antibodies can be produced by a stimulus such as viral [[Upper respiratory tract infection|URTI]] that exposes [[Alveolus|alveolar]] collagen membrane or it can be idiopathic. | ||
* The antibodies formed can act against alveolar membrane and lungs get involved in some cases such as in [[goodpasture syndrome]]. | * The antibodies formed can act against alveolar membrane and lungs get involved in some cases such as in [[goodpasture syndrome]]. | ||
| Line 24: | Line 25: | ||
* [[Connective tissue disease|Connective tissue disorders]] | * [[Connective tissue disease|Connective tissue disorders]] | ||
* [[Lupus nephritis]] | * [[Lupus nephritis]] | ||
* [[Henoch-Schönlein purpura|Henoch-Schönlein | * [[Henoch-Schönlein purpura|Henoch-Schönlein purpura]] | ||
* [[IgA nephropathy|Immunoglobulin A nephropathy]] | * [[IgA nephropathy|Immunoglobulin A nephropathy]] | ||
* Mixed [[cryoglobulinemia]] | * Mixed [[cryoglobulinemia]] | ||
| Line 30: | Line 31: | ||
===Type III=== | ===Type III=== | ||
* Type III RPGN is also known as pauci immune RPGN. | * Type III RPGN is also known as pauci immune RPGN<ref name="robbins" />. | ||
* There are no anti [[GBM]] antibodies or no [[Immune complex|immune complexes]] involved. | * There are no anti [[GBM]] antibodies or no [[Immune complex|immune complexes]] involved. | ||
* It | * It is further classified into 2 types: | ||
** Immunogenic - [[Anti-neutrophil cytoplasmic antibody|ANCA]] positive | |||
** Non immunogenic- ANCA negative/ Idiopathic | |||
* ANCAs cause the release of lytic enzymes from [[Neutrophil|neutrophils]] that damage the GBM. | |||
* Systemic [[vasculitis]] is present in most of the cases but some occur without systemic involvement and only renal findings maybe present. | * Systemic [[vasculitis]] is present in most of the cases but some occur without systemic involvement and only renal findings maybe present. | ||
* Examples include | * Examples include | ||
| Line 39: | Line 43: | ||
** Renal-limited necrotizing crescentic glomerulonephritis (NCGN) | ** Renal-limited necrotizing crescentic glomerulonephritis (NCGN) | ||
** [[Langerhans cell histiocytosis|Eosinophilic granulomatosis]] with polyangiitis (EGPA; Churg-Strauss syndrome) | ** [[Langerhans cell histiocytosis|Eosinophilic granulomatosis]] with polyangiitis (EGPA; Churg-Strauss syndrome) | ||
. | ** Drugs- [[hydralazine]], [[allopurinol]] and [[rifampin]]. | ||
==References== | ==References== | ||
Latest revision as of 19:26, 24 July 2018
|
Rapidly progressive glomerulonephritis Microchapters |
|
Differentiating Rapidly progressive glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Rapidly progressive glomerulonephritis classification On the Web |
|
American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis classification |
|
FDA on Rapidly progressive glomerulonephritis classification |
|
CDC on Rapidly progressive glomerulonephritis classification |
|
Rapidly progressive glomerulonephritis classification in the news |
|
Blogs on Rapidly progressive glomerulonephritis classification |
|
Directions to Hospitals Treating Rapidly progressive glomerulonephritis |
|
Risk calculators and risk factors for Rapidly progressive glomerulonephritis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
Rapidly progressive glomerulonephritis is classified on the basis of cause of glomerular injury.The immunoflourescent microspcopic findings are used in determining the cause of glomerular injury.
Classification
RPGN is classified on the basis of the cause of glomerular injury and the findings from light and immunofluorescence microscopy.[1][2].
Type I
- Type I RPGN is characterized by the presence of autoantibodies directed against the glomerular basement membrane (GBM)[3].
- Type I also known as anti-GBM glomerulonephritis.
- The antibodies formed are known as anticollagen antibodies and react against type IV collagen of GBM.[4]
- The antibodies can be produced by a stimulus such as viral URTI that exposes alveolar collagen membrane or it can be idiopathic.
- The antibodies formed can act against alveolar membrane and lungs get involved in some cases such as in goodpasture syndrome.
Type II
- Type II RPGN is caused by the deposition of immune complexes in the GBM.
- Immune complexes can be formed in certain infections or in connective tissue disorders.
- These immune complexes deposit over the GBM and activate the complement system resulting in crescent formation.
- Examples include:
- Postinfectious (staphylococci/streptococci)
- Connective tissue disorders
- Lupus nephritis
- Henoch-Schönlein purpura
- Immunoglobulin A nephropathy
- Mixed cryoglobulinemia
- Membranoproliferative glomerulonephritis
Type III
- Type III RPGN is also known as pauci immune RPGN[4].
- There are no anti GBM antibodies or no immune complexes involved.
- It is further classified into 2 types:
- Immunogenic - ANCA positive
- Non immunogenic- ANCA negative/ Idiopathic
- ANCAs cause the release of lytic enzymes from neutrophils that damage the GBM.
- Systemic vasculitis is present in most of the cases but some occur without systemic involvement and only renal findings maybe present.
- Examples include
- Granulomatosis with polyangiitis (Wegener granulomatosis)
- Microscopic polyangiitis (MPA)
- Renal-limited necrotizing crescentic glomerulonephritis (NCGN)
- Eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss syndrome)
- Drugs- hydralazine, allopurinol and rifampin.
References
- ↑ Couser WG (1988). "Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy". Am J Kidney Dis. 11 (6): 449–64. PMID 3287904.
- ↑ Couser WG (1998). "Pathogenesis of glomerular damage in glomerulonephritis". Nephrol Dial Transplant. 13 Suppl 1: 10–5. PMID 9507491.
- ↑ Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ; et al. (1996). "Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat". Am J Pathol. 149 (5): 1695–706. PMC 1865281. PMID 8909258.
- ↑ 4.0 4.1 Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, MO: Elsevier Saunders. pp. pp976–8. ISBN 0-7216-0187-1.